TrialSignal
Clinical trial intelligence report
A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 17, 2026
NCT ID
NCT03519880
Status
TERMINATED
Phase
NA
Sponsor
University of Michigan
Executive brief
Investment-Ready Snapshot
Non-invasive ventilation (NIV) is an important therapy for patients with a number of neurological diseases. Specifically, NIV has been shown to be an effective treatment for people with amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), which is a fatal, non-curable, progressive disease of the motor neurons. However, due to changes in facial structure associated with the disease, many ALS patients find that traditional NIV masks don't fit well. In this study, investigators will perform a feasibility study on NIV mask interfaces which are custom designed for each ALS patient and then manufactured via 3D printing.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03519880
Indication
Amyotrophic Lateral Sclerosis
Modality
medical device
Target
Custom Mask Interface
Intervention
Custom Mask Interface
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.